Key Drivers
- Positive EBITDA
- Negative Free Cash Flow
- Elevated Leverage
AIAI Summary
QDEL is a leveraged execution turnaround—not a simple value play—where stabilizing ex-China growth must quickly convert into restored gross margins and sustained free cash flow to support its ~$3.0B debt load; investors should wait for guidance delivery and cash-flow improvement before treating the depressed valuation as a durable opportunity.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Positive EBITDA
- •Negative Free Cash Flow
- •Elevated Leverage
QDEL's operational rebound is encouraging, but persistent losses, negative cash flow, high leverage, and declining liquidity make the low valuation a high-risk proposition.
Price Behavior
Key Price Behavior Insights:
- •Sustained downtrend
- •Fragile support
- •Failed rebound
QDEL remains bearish after a ~29% last-month decline, with $10.60 support fragile and a sustained break above $11.10–$11.80 needed to improve momentum.
Sharp ~29% decline over the last month, followed by a brief failed rebound
Sentiment & News
Key News Insights:
- •New institutional stake
- •Faster diagnostic focus
- •Clinical decision support
Squarepoint's new QDEL stake and QuidelOrtho's focus on faster diagnostics signal constructive institutional interest and innovation momentum.
The developments may support investor confidence in QuidelOrtho's diagnostic-growth strategy
Similar Companies in Healthcare
Other companies in the same sector with AI ratings